Oral semaglutide tablet

This invention

This invention is a high-dose oral tablet for treating obesity. It pairs 25 mg of semaglutide — a GLP-1 peptide — with the absorption enhancer SNAC, taken once daily. The gut normally destroys peptides and absorbs them poorly. SNAC helps the peptide survive that journey and cross the gut lining. The aim is weight-loss results comparable to weekly injected semaglutide, even though oral bioavailability sits around 1%. The work belongs to oral peptide drug delivery and pharmaceutical formulation.

Where it fits

Your idea lives in Pharmaceutical Preparations (A61K) and Therapeutic Drug Activity (A61P) — the formulation and treatment-use heart of this landscape. Both areas cluster tightly here, roughly 20–22× the corpus baseline. That simply reflects how focused this result set is on oral drug formulations for metabolic conditions — a well-developed, actively pursued corner. Filings appear steadily across two decades, with multiple filings in each year from 2013 to 2021 and new ones in 2023–2025. That's a healthy sign of ongoing activity. Among named players in this subset, Eli Lilly and Company, Merrion Research III Limited, and Axcess Limited have been active nearby in GLP-1, oral peptide enhancers, and absorption-boosting formulations. The field also connects to Peptides & Proteins (C07K), which these results touch only lightly.

Closest related work

US-9993430-B2 — Tablet formulation comprising semaglutide and a delivery agent (Novo Nordisk A/S · 13 citations · 13-member family)

This patent describes solid tablet compositions that combine a GLP-1 peptide with a delivery agent such as SNAC — the same core pairing your invention uses. It shows how Novo Nordisk A/S approached the central challenge of getting a peptide absorbed orally by co-formulating it with the same enhancer chemistry. It's the most directly on-point reference for seeing how the semaglutide-plus-SNAC tablet concept has been framed and built. Novo Nordisk holds 9 patents in this result set, though it doesn't appear in the top-assignee list above.

US-12396953-B2 — Solid compositions comprising a GLP-1 agonist and a salt of N-(8-(2-hydroxybenzoyl)amino)caprylic acid (Novo Nordisk A/S · 0 citations · 43-member family · filed 2025, recent)

This recent member of a long-running family covers solid compositions of a GLP-1 peptide together with a SNAC salt, plus their preparation processes and medical use. It shows how the same group has kept refining the formulation and manufacturing details over time. That makes it useful for understanding which aspects — granulation, salt form, dosing — have been explored and how the approach has evolved into newer filings.

US-8053429-B2 — Solid oral dosage form containing an enhancer (Merrion Research III Limited · 130 citations · 10-member family)

This widely cited patent describes solid oral dosage forms in which a medium-chain fatty acid salt or derivative enhances the bioavailability and absorption of an active ingredient. It shows a different but related route to the same problem your invention tackles — boosting absorption of a poorly bioavailable drug through an enhancer. It also offers context on the broader family of permeation-enhancer chemistries beyond SNAC itself.

US-10583177-B2 — Formulations for oral administration of active agents (Entera Bio Ltd · 3 citations · 71-member family)

This describes oral compositions that combine a therapeutically active agent, SNAC, and an antacid, arranged as a unit dosage form with a defined core. It shows how Entera Bio approached the same absorption challenge using SNAC alongside a pH-modifying component — an instructive variation on tuning the local gut environment to help a peptide get absorbed.

What you can do next

• Explore & build on it. Browse the related work above — new, differentiated ideas often come from combining or improving on existing approaches (a specific dose, granulation method, salt form, or patient-use regimen others haven't pinned down). Your 25 mg high-dose, once-daily, obesity-targeted angle is a concrete detail worth examining against what's already described.
• If you'd like to protect it. Filing a provisional application (usually with a patent attorney) is a common